ALPHABET

Randomized phase III trial of the administration of trastuzumab + Alpelisib +/- fulvestrant versus trastuzumab + chemotherapy in patients with a PIK3CA mutation and previously treated for advanced HER2+ cancer

Ouvert à Saint-Cloud depuis le : 12/12/2023
Public cible : Adult
Phase : Phase III

Description de l'essai

To determine whether alpelisib (PI3K inhibitor) + trastuzumab improves efficacy, measured by PFS (Progression Free Survival), compared to the combination of trastuzumab + chemotherapy (vinorelbine, capecitabine or eribulin) of the physician's choice, in patients with HER2+/RH-PIK3CA mutated advanced breast cancer.;À Determine whether alpelisib (PI3K inhibitor) + trastuzumab improves efficacy, measured by PFS (Progression Free Survival), compared to the combination of trastuzumab + chemotherapy (vinorelbine, capecitabine or eribulin) of the physician's choice, in patients with HER2+/RH+ PIK3CA mutated advanced breast cancer.

Url of the trial

Investigateur principal

FRANCOIS-CLEMENT BIDARD

Professeur - Médecin

Contacter